Across TCGA pan-cancer cohorts, SUPT3H Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SUPT3H data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SUPT3H Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUPT3H expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, BLCA, and COAD are the cancer types where SUPT3H Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.205	0.792	<.001	21	view →
BLCA	DFS	Median	III,IV	0.132	0.577	<.001	12	view →
COAD	DFS	Median	III,IV	0.035	0.698	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.959	0.626	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SUPT3H tumor-vs-normal RNA expression · all SUPT3H data types